{"id":"NCT01387737","sponsor":"Mitsubishi Tanabe Pharma Corporation","briefTitle":"Long-Term Safety Study of TA-7284 in Patients With Type 2 Diabetes Mellitus","officialTitle":"An Open-Label, Multicenter Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of TA-7284 in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-05","primaryCompletion":"2012-11","completion":"2012-12","firstPosted":"2011-07-06","resultsPosted":"2014-04-28","lastUpdate":"2014-06-06"},"enrollment":1299,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"TA-7284-Low","otherNames":[]},{"type":"DRUG","name":"TA-7284-High","otherNames":[]}],"arms":[{"label":"TA-7284-Low","type":"EXPERIMENTAL"},{"label":"TA-7284-High","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the safety and efficacy of TA-7284 as monotherapy or combination therapy with other oral anti-hyperglycaemic agent in Japanese patients with Type 2 diabetes mellitus on 52 weeks oral administration.","primaryOutcome":{"measure":"Safety and Tolerability Assessed by Adverse Events, Hypoglycemic Events","timeFrame":"54 weeks","effectByArm":[{"arm":"TA-7284-Low","deltaMin":81.8,"sd":null},{"arm":"TA-7284-High","deltaMin":82.8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":7,"countries":["Japan"]},"refs":{"pmids":["26530268","25802729"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":30,"n":584},"commonTop":["Nasopharyngitis","Hypoglycaemia unawareness","Upper respiratory tract inflammation","Hypoglycaemia","Constipation"]}}